Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Fortis Healthcare board okays extending MD & CEO Ashutosh Raghuvanshi's tenure by 2 years
Fortis Healthcare's board has approved Ashutosh Raghuvanshi's reappointment as Managing Director. His new term will commence on March 19, 2027, for a period of two years. This reappointment follows the conclusion of his current tenure on March 18, 2027. The board cited his expertise and role in the company's growth for this decision.
Cultural sensitivity, communication key to strengthening India's medical tourism appeal: IIM experts
Experts highlight cultural sensitivity and communication's importance for international medical tourists. Effective expectation management and communication enhance patient experiences in Indian hospitals. India is a leading medical tourism destination due to advanced healthcare and affordable costs. Hospitals should invest in intercultural communication training for professionals. Bridging cultural gaps improves patient satisfaction and India's market competitiveness.
Pharma stocks: Lupin, Torrent hit new peaks; Sun nears summit; here's why
Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.
Rajasthan recalls labour-inducing drug after quality test failure
A batch of Dinoprostone Gel, used to induce labour in pregnant women, has failed a government quality test, prompting Rajasthan's Drug Control Department to stop its use and recall the batch from hospitals across the state. The batch, manufactured by Cotec Healthcare, was found to be below prescribed quality standards after testing.
Marksans Pharma inks deal to acquire ABCnow GmbH
For a total consideration of 892,384
Marksans Pharma to acquire Germany-based ABCnow GmbH
Marksans Pharma announced its definitive agreement to acquire ABCnow GmbH. This German pharmaceutical distributor will be purchased for nearly ten crore rupees. The acquisition aims to expand Marksans' European market presence and distribution capabilities. It will allow the company to market its products directly within the EU. This strategic move is anticipated to conclude by July 2026.
Orchid Pharma soars on Exblifep commercialization deal in Russia
Orchid Pharma surged 8.51% to Rs 1,005.50 after the company has entered into licensing and supply agreement with Pharmasyntez JSC (Pharmasyntez) to commercialize anitbotic, Exblifep in Russia.
Marksans Pharma rises after acquiring 100% stake in ABCnow GmbH
Marksans Pharma added 3.77% to Rs 270.90 after the company said that it has entered into a definitive agreement to acquire 100% of the share capital of Germany-based ABCnow GmbH.
RBI to conduct Rs 25,000-cr overnight variable rate repo auction
The Reserve Bank of India (RBI) on Tuesday said it will conduct an overnight variable rate repo (VRR) auction for a notified amount of Rs 25,000 crore on July 8. The auction will take place between 9:30 am and 10:00 am on Wednesday, and the funds will be reversed on July 9, according to the RBI's notification. "On a review of current and evolving liquidity conditions, it has been decided to conduct a Variable Rate Repo (VRR) auction on Wednesday, July 8," the RBI said in a release.
Explained - Why this Smallcap Pharma stock jumped 13% for its best day in two years
Orchid's partnership with Pharmasyntez marks an important step in making Exblifep available to patients in Russia, according to Orchid Pharma Managing Director Manish Dhanuka.
Sun Pharma, Cipla Among Systematix's Top Pharma Picks Ahead Of Q1 Results — Full List Inside
Systematix estimates its healthcare coverage universe will post cumulative revenue growth of around 13% YoY.
Airtel to Trent: 44 stocks likely to report double-digit profit slump in Q1. Are your stocks on the list?
Motilal Oswal expects 44 companies, including Bharti Airtel, Trent, IndiGo, HAL, GAIL and Cipla, to report double-digit year-on-year profit declines in the June quarter. Higher energy costs, weaker demand, geopolitical tensions and margin pressure are expected to weigh on earnings, even as overall corporate profit growth slows in Q1.